Drug reference
ethylbiscoumacetate
Coumarin derivative, Vitamin K antagonist · Anticoagulant
Coumarin derivative, Vitamin K antagonistAnticoagulant
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Interferes with the synthesis of vitamin K dependent clotting factors in the liver by inhibiting vitamin K epoxide reductase.
Indications
Initiation of anticoagulation therapy (occasionally used, but difficult to maintain)
Dosing
- Adult
- Loading: 900 mg; Maintenance: 300–600 mg
Pharmacokinetics
Half-life
2 hours
Side effects
Common
AlopeciaBad taste
Related guidelines
GI bleeding on antiplatelet or anticoagulant therapy
CSI · Cardiology · 2020
Venous thromboembolism prophylaxis
ASH · Haematology · 2018
Anticoagulant management for dental procedures
ADA_DENTAL · Dentistry · 2015
Dialysis — initiation and maintenance
ISN_INDIA · Nephrology · 2023
Sickle cell disease
ASH · Haematology · 2020
Other Coumarin derivative, Vitamin K antagonist drugs
Ask House about ethylbiscoumacetate
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: KD Tripathi 7e·Updated: 2026-05-10